课题基金 / 基金详情

项目摘要

项目成果

Patricia W Finn的其他基金

相似基金

相关文献

中文摘要
翻译
免疫反应,包括由Toll样受体(TLR)4调节的免疫反应,为适应性过敏性疾病奠定了基础。 免疫反应我们的初步数据已经揭示了一种潜在的新的免疫途径,在肺部,通过连接TLR 4 细胞毒性T淋巴细胞抗原4(CTLA 4)的上调激活。我们证明CTLA 4信号可以 抑制实验性哮喘过敏反应。具体来说,我们发现阻断CTLA 4可以增加过敏性 过度表达CTLA 4抑制过敏性炎症,而过度表达CTLA 4抑制过敏性炎症。两种途径延伸了这些 调查结果。首先,先天性TLR 4配体在体外和体内均上调CTLA 4并抑制实验性哮喘;以及 与这一观察结果一致,TLR 4突变小鼠,其TLR 4应答缺陷, 应答其次,通过CD 45 RB信号增加CTLA 4,降低过敏反应。因为这三种分子 (CTLA 4、TLR 4和CD 45 RB)在调节性T细胞(T细胞)上表达,我们将研究T细胞在调节性T细胞中的功能。 TLR 4和CD 45 RB介导了对实验性哮喘的抑制作用。 有趣的是,我们的初步数据还表明,内毒素组分脂质A,这是一种TLR 4配体, 改善实验性哮喘。与我们的鼠类研究结果一致,流行病学研究表明, 内毒素丰富的环境降低了儿童哮喘的风险。此外,在我们的模型中, 细胞在体内增强过敏反应并阻断TLR 4配体介导的实验性哮喘抑制。这些 观察结果表明,TLR 4介导的哮喘抑制是由表达TLR 4的CTLA 4介导的。所以我们 假设TLR 4通过调节CTLA 4的上调来减弱适应性免疫应答, 抑制过敏性炎症的关键途径。 目的:通过确定CTLA 4在抑制过敏性炎症中的作用, CTLA 4(使用抗CTLA 4抗体或缺陷小鼠)促进过敏性炎症,以及如何增加CTLA 4 表达减少过敏性炎症(使用过表达CTLA 4或CD 45 RB的CTLA 4转基因 抗体)。目的二是研究TLR 4信号对CTLA 4表达的调节作用。目标3将决定 TLR 4信号抑制过敏性炎症的机制,包括细胞成分(APC,T细胞), 以及CTLA 4信号是否增强变应性炎症中TLR 4诱导的抑制活性。目标4将决定 TLR 4和CD 45 RB调节T细胞CTLA 4表达的分子机制, CTLA 4启动子区。该项目的目的是通过以下方法确定新的途径和潜在的治疗靶点: 先天免疫调节过敏性哮喘
英文摘要
e immune responses, including those modulated by Toll-like receptor (TLR) 4 set the stage for the adaptive allergic immune response. Our preliminary data has uncovered a potential novel immune pathway in the lung by linking TLR4 activation with upregulation of cytotoxic T lymphocyte antigen 4 (CTLA4). We demonstrate that CTLA4 signals can inhibit allergic responses in experimental asthma. Specifically, we show that blocking CTLA4 increases allergic inflammation, whereas over expression of CTLA4 suppresses allergic inflammation. Two pathways extend these findings. First, innate TLR4 ligands upregulate CTLA4 both in vitro and in vivo and inhibit experimental asthma; and consistent with this observation, TLR4 mutant mice, which have deficient TLR4 responses, have enhanced allergic responses. Second, increased CTLA4, by CD45RB signals, decreases allergic responses. Because all three molecules (CTLA4, TLR4, and CD45RB) are expressed on T regulatory (Tregs) cells, we will investigate the function of Tregs in the TLR4 and CD45RB mediated inhibition of experimental asthma. Interestingly, our preliminary data also shows that the endotoxin component lipid A, which is a TLR4 ligand, ameliorates experimental asthma. Consistent with our murine results, epidemiological studies show that exposure to an endotoxin rich environment decreases the risk of childhood asthma. Furthermore, in our model, the depletion of Treg cells in vivo enhances allergic responses and blocks TLR4 ligand mediated inhibition of experimental asthma. These observations indicate that TLR4 mediated suppression of asthma is mediated by CTLA4 expressing Tregs. Thus, our hypothesis is that TLR4 attenuates the adaptive immune response by modulating upregulation of CTLA4, a critical pathway in the suppression of allergic inflammation. Aim I will characterize the role of CTLA4 in the suppression of allergic inflammationby determining how inhibition of CTLA4 (using anti-CTLA4 antibody or deficient mice) promotes allergic inflammation, and how increased CTLA4 expression decreases allergic inflammation (using CTLA4 transgenics that over express CTLA4, or CD45RB antibody). Aim 2 will investigate whether TLR4 signals modulate CTLA4 expression in vivo. Aim 3 will determine the mechanisms by which TLR4 signals suppress allergic inflammation, including the cellular components (APC, T cells), and whether CTLA4 signals enhance TLR4 induced suppressor activity in allergic inflammation. Aim 4 will determine the molecular mechanisms by which TLR4 and CD45RB regulate CTLA4 expression in T cells by analysis of the CTLA4 promoter region. The objective of this project is to identify novel pathways, and potential therapeutic targets by which innate immunity modulates allergic asthma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Training in Respiratory Biology: Innovate, Integrate, and Translate
Pulmonary Interactions with Innate Immunity
Transplantation: Alloimmune Networks
Transplantation: Alloimmune Networks
海外基金